Palatin Technologies (PTN) Competitors $0.22 0.00 (-0.05%) As of 05/2/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock PTN vs. ENLV, CDIO, LIAN, LSTA, PMN, BIVI, CVM, LEXX, ELEV, and QNTMShould you be buying Palatin Technologies stock or one of its competitors? The main competitors of Palatin Technologies include Enlivex Therapeutics (ENLV), Cardio Diagnostics (CDIO), LianBio (LIAN), Lisata Therapeutics (LSTA), ProMIS Neurosciences (PMN), BioVie (BIVI), CEL-SCI (CVM), Lexaria Bioscience (LEXX), Elevation Oncology (ELEV), and Quantum Biopharma (QNTM). These companies are all part of the "pharmaceutical products" industry. Palatin Technologies vs. Enlivex Therapeutics Cardio Diagnostics LianBio Lisata Therapeutics ProMIS Neurosciences BioVie CEL-SCI Lexaria Bioscience Elevation Oncology Quantum Biopharma Enlivex Therapeutics (NASDAQ:ENLV) and Palatin Technologies (NYSE:PTN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment. Does the MarketBeat Community believe in ENLV or PTN? Enlivex Therapeutics received 60 more outperform votes than Palatin Technologies when rated by MarketBeat users. Likewise, 81.08% of users gave Enlivex Therapeutics an outperform vote while only 0.00% of users gave Palatin Technologies an outperform vote. CompanyUnderperformOutperformEnlivex TherapeuticsOutperform Votes6081.08% Underperform Votes1418.92%Palatin TechnologiesOutperform VotesNo VotesUnderperform Votes3100.00% Which has more risk and volatility, ENLV or PTN? Enlivex Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Palatin Technologies has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Which has better earnings and valuation, ENLV or PTN? Enlivex Therapeutics has higher earnings, but lower revenue than Palatin Technologies. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Palatin Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$29.07M-$0.73-1.42Palatin Technologies$350K16.19-$40.31M-$1.55-0.14 Do analysts rate ENLV or PTN? Enlivex Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 861.54%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Enlivex Therapeutics is more favorable than Palatin Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Palatin Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals have more ownership in ENLV or PTN? 1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Palatin Technologies shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 7.1% of Palatin Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is ENLV or PTN more profitable? Palatin Technologies' return on equity of 0.00% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -67.57% -58.45% Palatin Technologies N/A N/A N/A Does the media favor ENLV or PTN? In the previous week, Palatin Technologies had 3 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 3 mentions for Palatin Technologies and 0 mentions for Enlivex Therapeutics. Palatin Technologies' average media sentiment score of 0.58 beat Enlivex Therapeutics' score of 0.00 indicating that Palatin Technologies is being referred to more favorably in the news media. Company Overall Sentiment Enlivex Therapeutics Neutral Palatin Technologies Positive SummaryEnlivex Therapeutics beats Palatin Technologies on 9 of the 17 factors compared between the two stocks. Get Palatin Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTN vs. The Competition Export to ExcelMetricPalatin TechnologiesPharmaceutical Preparations IndustryManufacturing SectorNYSE ExchangeMarket Cap$5.67M$6.86B$2.06B$19.21BDividend YieldN/A2.90%2.71%4.01%P/E Ratio-0.147.5422.6933.50Price / Sales16.19259.7063.8029.16Price / CashN/A65.8551.7217.52Price / BookN/A6.562.004.55Net Income-$40.31M$143.88M-$385.85M$1.02B7 Day Performance5.27%3.35%1.39%2.30%1 Month PerformanceN/A15.83%5.83%8.54%1 Year PerformanceN/A-3.19%7.91%4.75% Palatin Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTNPalatin TechnologiesN/A$0.220.0%N/AN/A$5.67M$350,000.00-0.1430Analyst ForecastENLVEnlivex Therapeutics2.695 of 5 stars$1.05-0.5%$10.00+856.9%-35.8%$22.37MN/A-1.0770Positive NewsCDIOCardio Diagnostics1.6828 of 5 stars$0.42+6.8%$2.00+371.7%-44.3%$21.85M$34,890.000.001Gap UpLIANLianBioN/A$0.20flatN/A-36.3%$21.61MN/A-0.25110News CoverageGap DownLSTALisata Therapeutics2.3211 of 5 stars$2.48+2.7%$15.00+506.1%-15.4%$21.45M$1M-0.9930Upcoming EarningsShort Interest ↓News CoverageGap UpPMNProMIS Neurosciences2.0215 of 5 stars$0.65+0.5%$6.00+818.8%-67.3%$21.35MN/A-6.535Positive NewsGap UpBIVIBioVie2.6356 of 5 stars$1.18+36.3%$3.00+155.3%+146.7%$21.16MN/A-0.1210Short Interest ↓Gap UpHigh Trading VolumeCVMCEL-SCIN/A$0.25-5.3%N/A-84.6%$21.03MN/A-0.5243Analyst ForecastNews CoverageHigh Trading VolumeLEXXLexaria Bioscience2.4572 of 5 stars$1.20-2.8%$7.00+485.8%-62.0%$20.98M$525,923.00-2.397Short Interest ↓ELEVElevation Oncology2.6534 of 5 stars$0.35+3.2%$3.39+864.6%-90.5%$20.97MN/A-0.4340Positive NewsQNTMQuantum BiopharmaN/A$7.73+13.7%N/AN/A$20.96MN/A-0.50N/AUpcoming Earnings Related Companies and Tools Related Companies Enlivex Therapeutics Alternatives Cardio Diagnostics Alternatives LianBio Alternatives Lisata Therapeutics Alternatives ProMIS Neurosciences Alternatives BioVie Alternatives CEL-SCI Alternatives Lexaria Bioscience Alternatives Elevation Oncology Alternatives Quantum Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PTN) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palatin Technologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Palatin Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTN Stock Free PTN Stock Alerts